文献速递妇科

单药卡铂AUC4双周方案二线治疗甲氨蝶呤耐药低危妊娠滋养细胞肿瘤的疗效分析

Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
PubMed 文献 · Gynecol Oncol · 2023-06-14

本研究评估单药卡铂AUC4双周方案作为甲氨蝶呤耐药低危妊娠滋养细胞肿瘤二线治疗的疗效。22例可评估患者中,36%获得hCG完全缓解,所有未缓解者经后续联合化疗治愈,总生存率100%。作者认为卡铂二线活性不足,需新策略提高hCG完全缓解率并减少毒性联合化疗。

要点

  • 甲氨蝶呤耐药后单药卡铂AUC4双周方案hCG完全缓解率仅36%。
  • 14例未获hCG完全缓解者经后续联合化疗均治愈,总生存率100%。
  • 作者认为卡铂二线活性不足,需新策略提高缓解率并减少联合化疗暴露。

核心结论

  • 卡铂在低危甲氨蝶呤耐药妊娠滋养细胞肿瘤二线治疗中活性不足,需要新策略提高hCG完全缓解率并减少毒性联合化疗方案的使用。

研究设计与样本

  • 2017年起单药卡铂成为甲氨蝶呤耐药后hCG>3000 IU/L时的全国标准二线治疗,改为双周AUC4方案,持续至hCG正常后加3个巩固周期。
  • 共22例可评估患者接受卡铂AUC4双周方案,甲氨蝶呤耐药时中位hCG为10147 IU/L(IQR 5527-19639),中位周期数6(IQR 2-8)。

主要发现

  • 22例可评估患者中36%获得hCG完全缓解。
  • 14例未获hCG完全缓解者均经后续联合化疗治愈,其中11例接受三线联合化疗、2例接受四线联合化疗、1例接受五线联合化疗及子宫切除。
  • 总生存率维持100%。

临床怎么用

  • 原文结论指出卡铂在低危甲氨蝶呤耐药妊娠滋养细胞肿瘤二线治疗中活性不足,需要新策略提高hCG完全缓解率并减少毒性联合化疗方案的使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately one-third of patients with low-risk Gestational Trophoblastic Neoplasia (WHO 0-6) develop methotrexate-resistance (MTX-R). In the UK, subsequent treatment with either actinomycin-D (ActD) or multi-agent combination chemotherapy has depended on whether the hCG was above or below an hCG threshold. To reduce exposure to combination chemotherapy (CC), over the years the UK service has raised this threshold as well as using single-agent carboplatin AUC6 3-weekly at MTX-R instead of CC. Updated results for carboplatin demonstrate an 86% complete hCG response (hCG CR) but associated with haematological dose-limiting toxicity. METHODS: In 2017, single-agent carboplatin became the national standard second-line treatment following MTX-R at hCG of >3000 IU/L. Carboplatin was changed to two-weekly AUC4 scheduling and continued until normal hCG plus 3 consolidation cycles. For patients failing to respond, CC (Etoposide-Actinomycin-D or EMA-CO) was introduced. RESULTS: 22 evaluable patients with a median hCG at MTX-R of 10,147 IU/L (IQR 5527-19,639) received carboplatin AUC4 2-weekly (median no. of cycles = 6, IQR 2-8). Of these, 36% achieved a hCG CR. All 14 non-CR patients were cured with subsequent CC; 11 and 2 patients with 3rd line and 4th line CC respectively and 1 patient following 5th line CC and hysterectomy. Overall survival remains 100%. CONCLUSION: Carboplatin is not sufficiently active in the second-line treatment of low-risk MTX-resistant GTN. New strategies are required to increase hCG CR and spare more toxic CC regimens.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Winter MC, Tidy JA, Singh K, et al. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN). Gynecol Oncol. 2023. PMID: 37327541. doi:10.1016/j.ygyno.2023.05.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。